Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection.
about
Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxThe Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian AmazonPlatform for Plasmodium vivax vaccine discovery and developmentThe Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic VariantsNaturally acquired antibodies to Plasmodium vivax Duffy binding protein (DBP) in Brazilian Amazon.Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.Malaria in Brazil: an overview.Worldwide genetic variability of the Duffy binding protein: insights into Plasmodium vivax vaccine developmentPredicting the Origins of Anti-Blood Group Antibody Specificity: A Case Study of the ABO A- and B-Antigens.Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.Evaluation of the naturally acquired antibody immune response to the Pv200L N-terminal fragment of Plasmodium vivax merozoite surface protein-1 in four areas of the Amazon Region of Brazil.Antigenicity and immunogenicity of Plasmodium vivax merozoite surface protein-3.Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding proteinAntibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmissionDuffy antigen receptor for chemokine (DARC) polymorphisms and its involvement in acquisition of inhibitory anti-duffy binding protein II (DBPII) immunity.Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein.Plasmodium simium, a Plasmodium vivax-related malaria parasite: genetic variability of Duffy binding protein II and the Duffy antigen/receptor for chemokines.Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies.A Library of Plasmodium vivax Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein InteractionsStandardization and validation of a cytometric bead assay to assess antibodies to multiple Plasmodium falciparum recombinant antigensThe Plasmodium vivax merozoite surface protein 1 paralog is a novel erythrocyte-binding ligand of P. vivax.Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein.What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates?Insights into the naturally acquired immune response to Plasmodium vivax malaria.Immunogenicity of glycosylphosphatidylinositol-anchored micronemal antigen in natural Plasmodium vivax exposure.Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.The Biology of Plasmodium vivax.Natural acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein (PvDBP-II) equally block erythrocyte binding of homologous and heterologous expressed PvDBP-II on the surface of COS-7 cells.The role of the human Duffy antigen receptor for chemokines in malaria susceptibility: current opinions and future treatment prospects.Plasmodium vivax Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well-consolidated settlement of the Amazon Region.An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies.Applying pose clustering and MD simulations to eliminate false positives in molecular docking.Identification and immunological characterization of the ligand domain of Plasmodium vivax reticulocyte binding protein 1a.Blood-stage Plasmodium vivax antibody dynamics in a low transmission setting: A nine year follow-up study in the Amazon region
P2860
Q24273364-2160AE56-4FD2-4560-9AAF-C241862F8CF6Q27009149-3A0AC373-ECFB-4D0C-B50B-07ABC369C2E8Q27021891-6325C534-D5B1-4CBC-BD38-19CA0D0A6E5AQ28396379-0E17E55E-213A-45E1-9ED4-314540B32C6DQ33617528-7A2957EB-6EFA-410A-84EB-A513699BD778Q33798074-9E24A1C3-6435-487F-803F-CAED04857C64Q33939774-AC96F7CC-2BE9-428A-935B-9594B0A9C636Q33988630-D6E10045-5A13-4AD3-81AC-F4D2E5764E1CQ34076811-22B4CE1B-9C6A-448D-BD86-16C1DEC7A0EFQ34260750-2237E2DE-1378-496E-9ABF-B400A507B922Q34546246-6C2937FE-077F-41D7-B5C2-1B7CFA3B4327Q34606478-024F8B40-C0FB-4AF1-B14B-07CBA5F2179CQ34994491-6A2C47B6-8742-49BA-BB31-5C396AABBA9BQ35031922-3B0B63BA-CB91-41E3-B32C-FD87DF4D0138Q35141958-A05D3638-F400-4D7C-BA68-27F513BC46BDQ35666191-0166692A-99BD-4C7F-A3E9-6F038264332DQ35673121-64B64A6C-3883-4719-95F3-FF4EE403DC82Q35805433-0710F85D-FE64-4DE6-9F70-5630FFA70C62Q35877857-40A0E2C6-2D48-417B-BA65-761A1D9212A6Q36539299-62087DA9-0D4A-43C1-BD86-2D5B1D34D93BQ36826946-8FB8DFAC-8880-4C8C-A3BC-8424E3EFC822Q36978206-787103E6-A6F5-4DC4-9ACA-2F26835D0754Q37638131-12215200-9799-4E02-89E6-A2F0E658575FQ38728598-1A9D85B3-909E-4E24-B4D3-46169D878584Q38938701-6637A498-A01F-41EE-B966-738DA52F9A86Q39115271-0EBC21D7-A48E-464E-812C-4BEE6811CF3DQ40218474-D3F386E1-59BE-40D8-ABF7-B7DBD08AC071Q41071739-283BAA26-273E-40DC-B2F3-D25363C5354DQ41707671-DDFCE196-9B8B-4A8B-AD0F-DDECFA368209Q44164222-FC6F6433-E6E8-4239-914D-4D5604ED8A0CQ47150417-DAF5ED62-5C15-4229-8CAA-75A1D212474AQ50067648-F8C93E54-D69A-4E00-B935-469EA4FF5E80Q54217362-802E6ABC-CC9E-4B65-8B1C-CB75788B111AQ59129806-D089C5E6-A478-4E3B-B6C0-EA339D734738
P2860
Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Naturally acquired inhibitory ...... ng a single malaria infection.
@en
Naturally acquired inhibitory ...... ng a single malaria infection.
@nl
type
label
Naturally acquired inhibitory ...... ng a single malaria infection.
@en
Naturally acquired inhibitory ...... ng a single malaria infection.
@nl
prefLabel
Naturally acquired inhibitory ...... ng a single malaria infection.
@en
Naturally acquired inhibitory ...... ng a single malaria infection.
@nl
P2093
P2860
P921
P1476
Naturally acquired inhibitory ...... ng a single malaria infection.
@en
P2093
A M McHenry
B A M Sanchez
B M Guerra
C F A Brito
I P Ceravolo
I S Soares
L H Carvalho
P2860
P304
P356
10.1111/J.1365-2249.2009.03931.X
P577
2009-06-01T00:00:00Z